The original idea of organs on a chip caught everyone’s interest, but like most areas of new research, progress has been slower than expected. Part of this is related to the new techniques themselves, but this article in today’s Nature Medicine shows that part of the problem is due to some non-alignments between the researchers who are developing the chips and the pharmaceutical companies who currently would be the main customers. Researchers have different interests and needs than pharma companies, and a better understanding of pharma’s requirements will be needed for them to continue to provide financial support. That being said, the long-term propects for this technology seem very good.
See link to article here.